<DOC>
	<DOCNO>NCT01289301</DOCNO>
	<brief_summary>Polyomavirus BK nephropathy serious complication renal transplantation lead graft loss 40 % case . Since virustatic drug exists , investigator want study best way manage viral invasion change immunosuppressive treatment compare two treatment scheme . The investigator hypothesis switch mTOR-based scheme superior general decrease calcineurin inhibitor ( CNI ) -based scheme . The study perform prospective , randomize , parallel group comparison .</brief_summary>
	<brief_title>Studying Effect Changing Immunosuppression Case Polyoma BK Virus Infection Renal Transplant</brief_title>
	<detailed_description>The study group ( n=62 ) switch CNI everolimus control group ( n=62 ) get general reduction CNI-based immunosuppression . Follow-up duration intervention per patient 24 month , duration trial 72 month include 4 year recruitment .</detailed_description>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>precede renal transplantation function graft permanent creatinine clearance 25mL/min biopsyconfirmed polyoma BK virus nephropathy age 18 year old allergy nontolerance study medication everolimus pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>renal transplantation</keyword>
	<keyword>polyoma BK virus infection</keyword>
	<keyword>everolimus</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>